Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.
| Traded as | Nasdaq: ONCY |
|---|---|
| ISIN | US6823108757 |
| CIK | 0001129928 |
| LEI | — |
| EIN | 980541667 |
| Sector | — |
|---|---|
| Industry | Pharmaceutical Preparations |
| CEO | — |
| Employees | — |
| Fiscal Year End | 1231 |
| Address | SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121 |
|---|---|
| Phone | 4036707377 |
| Website | http://www.oncolyticsbiotech.com |
Get over a decade of historical stock quotes data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ONCY | ONCOLYTICS BIOTECH INC | 2026-04-15 15:04:25 | 1.1 | 0 | 0 |
Get over a decade of historical company information data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ONCY | 0001129928 | ONCOLYTICS BIOTECH INC | US6823108757 | — | 980541667 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | NV | SUITE 325, 4350 EXECUTIVE DRIVE | SAN DIEGO | CA | 92121 | UNITED STATES | US | 4036707377 | SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121 | SUITE 325, 4350 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121 | — | — | 1998 | — | — | http://www.oncolyticsbiotech.com | 72,100,000 | 108,021,271 | 116,128,162 | Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. | 2026-04-09 19:45:45 |
Get over a decade of historical stock price data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
Get over a decade of historical stock price data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
Get over a decade of historical market cap data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 72,100,000 | 72,100,000 | 100 | 116,128,162 | 116,128,162 | 100 |
Get over a decade of historical income statement data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| Fiscal Year | 2025 |
|---|---|
| Revenue | — |
| Cost Of Revenue | — |
| Gross Profit | — |
| Research And Development Expenses | 13,314,000 |
| General And Administrative Expenses | 15,411,000 |
| Operating Expenses | 28,725,000 |
| Operating Income | -28,725,000 |
| Net Income | -28,759,000 |
| Earnings Per Share Basic | -0.3 |
| Earnings Per Share Diluted | -0.3 |
| Weighted Average Shares Outstanding Basic | 95,857,147 |
| Weighted Average Shares Outstanding Diluted | 95,857,147 |
Get over a decade of historical balance sheet statement data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| Fiscal Year | 2025 |
|---|---|
| Cash And Cash Equivalents | 5,202,000 |
| Marketable Securities Current | — |
| Accounts Receivable | — |
| Inventories | — |
| Non Trade Receivables | — |
| Other Assets Current | 1,069,000 |
| Total Assets Current | 6,844,000 |
| Marketable Securities Non Current | — |
| Property Plant And Equipment | 228,000 |
| Other Assets Non Current | — |
| Total Assets Non Current | 738,000 |
| Total Assets | 7,582,000 |
| Accounts Payable | 3,504,000 |
| Deferred Revenue | — |
| Short Term Debt | — |
| Other Liabilities Current | 0 |
| Total Liabilities Current | 6,101,000 |
| Long Term Debt | — |
| Other Liabilities Non Current | — |
| Total Liabilities Non Current | 5,280,000 |
| Total Liabilities | 11,381,000 |
| Common Stock | 0 |
| Retained Earnings | -429,495,000 |
| Accumulated Other Comprehensive Income | 6,225,000 |
| Total Shareholders Equity | -3,799,000 |
Get over a decade of historical cash flow statement data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| Fiscal Year | 2025 |
|---|---|
| Depreciation And Amortization | 70,000 |
| Share Based Compensation Expense | 3,104,000 |
| Other Non Cash Income Expense | — |
| Change In Accounts Receivable | — |
| Change In Inventories | — |
| Change In Non Trade Receivables | -3,000 |
| Change In Other Assets | — |
| Change In Accounts Payable | 2,932,000 |
| Change In Other Liabilities | -360,000 |
| Cash From Operating Activities | -20,112,000 |
| Purchases Of Marketable Securities | — |
| Sales Of Marketable Securities | — |
| Acquisition Of Property Plant And Equipment | 6,000 |
| Acquisition Of Business | — |
| Other Investing Activities | — |
| Cash From Investing Activities | -6,000 |
| Tax Withholding For Share Based Compensation | — |
| Payments Of Dividends | — |
| Issuance Of Common Stock | 11,767,000 |
| Repurchase Of Common Stock | — |
| Issuance Of Long Term Debt | — |
| Repayment Of Long Term Debt | — |
| Other Financing Activities | -27,000 |
| Cash From Financing Activities | 14,120,000 |
| Change In Cash | -5,877,000 |
| Cash At End Of Period | 5,202,000 |
| Income Taxes Paid | 67,000 |
| Interest Paid | — |
Get over a decade of historical insider transactions data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Kelly Jared | Director, Chief Executive Officer | 2026-03-12 | 5,050 | A | 114,050 |
| Parsons James T. | Director | 2026-03-11 | 10,000 | A | 41,849 |
| Andrews Patricia S | Director | 2026-02-12 | 35,400 | A | 78,128 |
| Seizinger Bernd R. | Director | 2026-02-12 | 40,000 | A | 566,991 |
| Hagerman Allison | VP, Product Development | 2026-02-12 | 10,000 | A | 115,059 |
Get over a decade of historical institutional holdings data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 148,492 | 169,899 | 0.874 |
| Rockefeller Capital Management L.P. | 2025-12-31 | 18,301 | 20,939 | 0.874 |
| Virtu Financial LLC | 2025-12-31 | 68,000 | 77,883 | 0.8731 |
| Connective Capital Management, LLC | 2025-12-31 | 131,397 | 150,340 | 0.874 |
| RAYMOND JAMES FINANCIAL INC | 2025-12-31 | 29,164 | 33,368 | 0.874 |
Get over a decade of historical mutual fund holdings data and access to complete datasets. Unlock API access, unlimited Excel and CSV downloads, and exclusive data collections, all available with a paid subscription.
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| FIDELITY CONCORD STREET TRUST | 2025-11-30 | Fidelity Nasdaq Composite Index Fund | FNCMX | 66,939 | 66,724.8 | 0.0003 |
| FIDELITY CONCORD STREET TRUST | 2025-08-31 | Fidelity Nasdaq Composite Index Fund | FNCMX | 66,939 | 69,616.56 | 0.0003 |
| FIDELITY CONCORD STREET TRUST | 2025-05-31 | Fidelity Nasdaq Composite Index Fund | FNCMX | 66,939 | 22,759.26 | 0.0001 |
| FIDELITY CONCORD STREET TRUST | 2025-02-28 | Fidelity Nasdaq Composite Index Fund | FNCMX | 66,939 | 44,233.29 | 0.0002 |
| FIDELITY CONCORD STREET TRUST | 2024-11-30 | Fidelity Nasdaq Composite Index Fund | FNCMX | 41,942 | 39,320.63 | 0.0002 |
